



Commercial/Healthcare Exchange PA Criteria

Effective: August 2017

Prior Authorization: Steroid Inhalers

Products Affected: Alvesco (ciclesonide) oral inhalation; ArmonAir Digihaler (fluticasone); Fluticasone propionate HFA oral inhalation

Medication Description: Ciclesonide is a non-halogenated glucocorticoid which is beneficial in treating inflammatory conditions such as allergic rhinitis and asthma. Fluticasone oral inhalation products are used for the maintenance treatment of asthma. Orally inhaled corticosteroids (ICS) are considered a preferred pharmacologic treatment in the long-term management of persistent asthma.

Covered Uses: Maintenance treatment of asthma as prophylactic therapy

Exclusion Criteria: Status asthmaticus or other acute episodes of asthma

Required Medical Information:

1. Diagnosis
2. Previous medications tried/failed

Age Restrictions:

1. 12 years of age and older
2. 4 years of age and older (Fluticasone propionate HFA oral inhalation)

Prescriber Restrictions: None

Coverage Duration: 12 months

Other Criteria:

Alvesco:

- A. Patient has a diagnosis of Asthma; **AND**
- B. Patient has had a documented trial and failure of at least **TWO** of the following medications:
 - Asmanex
 - Flovent
 - Arnuity Ellipta
 - Pulmicort

ArmonAir & Fluticasone propionate HFA

- A. Patient has a diagnosis of Asthma; **AND**
- B. Patient has had a documented trial and failure of at least **TWO** of the following medications:
 - Asmanex
 - Flovent

Last Res. October 2022



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.



- Arnuity Ellipta
- Pulmicort

References:

1. Alvesco (ciclesonide) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; March 2018.
2. Product Information: ARMONAIR(TM) RESPICLICK(R) inhalation powder, fluticasone propionate inhalation powder. Teva Respiratory, LLC (per manufacturer), Frazer, PA, 2017.

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	8/2017
2	Update	Removed affected products from CCI Inhalers Policy and created Steroid Inhalers Policy; Adopted EH template specified criteria; CCI P&T Review History: 8/17, 11/17, 11/18; CCI Revision Record: 11/17	All	1/13/2020
3	Update	Removed: For Healthcare Exchange members only on Alvesco.	Other criteria	3/26/2021
4	Update	Updated products affected to include Fluticasone propionate HFA oral inhalation	Products affected, Other Criteria, Age restriction	8/29/2022
5	Update	Affected Products: remove ArmonAir Respiclick (discontinued), add ArmonAir Digihaler	Products Affected	10/3/2022

Last Res. October 2022